[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cerebral-venous-sinus-thrombosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cerebral-venous-sinus-thrombosis":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,80,106,128,155,181],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":26,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100356308","cerebral-venous-thrombosis-cohort-study-in-china-mainland-100356308",false,"NCT03919305","Cerebral Venous Thrombosis Cohort Study in China Mainland","CCC","Inclusion Criteria:\n\n• Cerebral venous sinus thrombosis, deep cerebral vein thrombosis and cortical vein thrombosis diagnosed by digital subtraction angiography (DSA), magnetic resonance venography (MRV), computed tomography venography (CTV) or high-resolution magnetic resonance imaging (HR-MRI).\n\nExclusion Criteria:\n\n• None of the patient, trustee or immediate family members signed the informed consent.","ALL",{"count":18,"type":19},3000,"ESTIMATED","OBSERVATIONAL","This study was aimed to reveal the clinical features,natural history of the diseases and current therapeutic situations of cerebral venous thrombosis (CVT) in China mainland. Blood samples and cerebrospinal fluid samples will be collected after recruitment to reveal the pathological mechanisms of CVT and identify the biomarkers for CVT.",[23,24,25],"Cerebral Venous Sinus Thrombosis","Deep Cerebral Vein Thrombosis","Cortical Vein Thrombosis",[27,28,29,30,31,32,33,34],"Cerebral venous sinus thrombosis","Deep cerebral vein thrombosis","Cortical vein thrombosis","Cohort study","Real world evidence","Observational study","China mainland","Cerebral venous system thrombosis","RECRUITING","2026-05-29",{"date":38,"type":39},"2026-06-02","ACTUAL",{"date":41,"type":39},"2019-01-01",{"date":43,"type":19},"2026-12-31",{"name":45,"class":46},"Capital Medical University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100635104","mena-regional-endovascular-intervention-for-venous-cerebral-venous-sinus-thrombosis-100635104","NCT07548346","MENA Regional Endovascular Intervention for Venous Cerebral Venous Sinus Thrombosis","REVIVE-CVST: A Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint (PROBE) Trial of Endovascular Thrombectomy Plus Standard Medical Care Versus Standard Medical Care Alone in Adults With Acute or Subacute Cerebral Venous Sinus Thrombosis at High Risk of Poor Outcome in the Middle East and North Africa Region","REVIVE-CVST","Inclusion Criteria:\n\n* Age 18-65 years, inclusive\n* Radiologically confirmed cerebral venous sinus thrombosis (CVST) by CT venography (CTV), MR venography (MRV), or digital subtraction angiography (DSA), with thrombosis of at least one major dural sinus\n* Acute or subacute presentation with symptom onset within 21 days of randomization\n* MRI phase characterization confirming acute or subacute phase\n* At least one risk factor for poor outcome: symptoms of intracranial hypertension (severe headache, papilledema, visual obscurations), focal neurological deficit, seizures, altered consciousness (GCS 9-14), intracranial hemorrhage from venous congestion, or deep venous system thrombosis\n* Significant venous outflow obstruction on imaging\n* Written informed consent from patient or legally authorized representative\n\nExclusion Criteria:\n\n* Isolated cortical vein thrombosis without dural sinus involvement\n* Isolated cavernous sinus thrombosis\n* Chronic-phase CVST on MRI phase characterization\n* Pre-morbid modified Rankin Scale (mRS) score greater than 2\n* Glasgow Coma Scale (GCS) score less than 9 at randomization\n* Imminent risk of transtentorial herniation requiring emergent decompressive craniectomy\n* Massive cerebral edema with midline shift greater than 10 mm requiring surgical intervention\n* Active systemic bleeding or hemorrhagic diathesis\n* Severe allergy to iodinated contrast media\n* CVST secondary to active hematological malignancy or life expectancy less than 12 months\n* Pregnancy\n* Participation in another interventional clinical trial within 30 days\n* Any condition rendering the patient unsuitable for study participation per investigator judgment","18 Years","65 Years",{"count":59,"type":19},440,"INTERVENTIONAL",[62],"NA","REVIVE-CVST is a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) trial evaluating whether early endovascular thrombectomy (EVT) combined with standard anticoagulation improves outcomes compared to anticoagulation alone in patients with severe cerebral venous sinus thrombosis (CVST).\n\nThe study targets adult patients (aged 18 years or older) presenting within 14 days of symptom onset with imaging-confirmed CVST and at least one severity marker, such as a Glasgow Coma Scale score of 14 or below, intracerebral hemorrhage, venous infarction, or deep venous system involvement.\n\nParticipants will be randomly assigned in a 1:1 ratio to either the intervention arm (EVT plus anticoagulation) or the control arm (anticoagulation alone). The primary endpoint is functional outcome at 180 days as measured by the modified Rankin Scale (mRS), using a shift analysis across all mRS categories.\n\nThe trial aims to enroll 440 participants across approximately 15 centers in the Middle East, North Africa, South Asia, and Turkey (MENA-SINO network). The study duration is approximately 42 months, including 18 months of enrollment and 12 months of follow-up for the last enrolled patient.",[23],[66,67,68],"CVST","endovascular thrombectomy","anticoagulation","NOT_YET_RECRUITING","2026-04-16",{"date":72,"type":39},"2026-04-23",{"date":74,"type":19},"2026-07",{"date":76,"type":19},"2030-01",{"name":78,"class":46},"Middle East North Africa Stroke and Interventional Neurotherapies Organization",14,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":47},"100598528","glymphatic-function-and-white-matter-integrity-in-cerebral-venous-disorders-100598528","NCT07072663","Glymphatic Function and White Matter Integrity in Cerebral Venous Disorders","Glymphatic Function and White Matter Integrity in Cerebral Venous Disorders: A Prospective Cohort Study","1. Subjects with Cerebral Venous Sinus Stenosis\n\n   Inclusion Criteria:\n   * Age ≥18 years, any gender;\n   * Definite diagnosis of cerebral venous sinus stenosis confirmed by clinical and imaging examinations;\n   * Stenosis limited to the transverse sinus and\u002For sigmoid sinus, presenting as moderate to severe localized stenosis or occlusion (stenosis degree ≥50%), with or without internal jugular vein stenosis;\n   * The subject or their legal representative signs a written informed consent form.\n\n   Exclusion Criteria:\n   * Simple anatomical variation or physiological narrowing of the cerebral venous sinus\u002Finternal jugular vein without definitive evidence of localized stenosis;\n   * Complicated by cerebral venous sinus\u002Fcortical vein\u002Finternal jugular vein thrombosis;\n   * Prior receipt of endovascular treatment for cerebral venous sinus\u002Finternal jugular vein, ventricular puncture drainage, or lumbar cistern drainage before enrollment;\n   * Presence of moderate to severe stenosis (≥50%) in intracranial or extracranial arteries;\n   * History of cerebral infarction, cerebral hemorrhage, or neurosurgery;\n   * Complicated by other neurological structural abnormalities such as cerebral small vessel disease, intracranial vascular malformation, dural arteriovenous fistula, intracranial infection, intracranial space-occupying lesion, severe cerebral atrophy, or hydrocephalus;\n   * Presence of other diseases affecting glymphatic function (e.g., multiple sclerosis, neuromyelitis optica spectrum disorders, systemic lupus erythematosus, obstructive sleep apnea-hypopnea syndrome, Parkinson's disease, or Alzheimer's disease);\n   * Contraindications to MRI (e.g., metal implants, claustrophobia, etc.) or allergy to gadolinium-based contrast agents;\n   * Other conditions deemed unsuitable for enrollment by the investigator.\n2. Subjects with Cerebral Venous Sinus Thrombosis\n\n   Inclusion Criteria:\n   * Age ≥18 years, any gender;\n   * Definite diagnosis of acute or subacute phase (onset to diagnosis ≤28 days) cerebral venous sinus thrombosis, with or without internal jugular vein thrombosis, confirmed by clinical and imaging examinations;\n   * The subject or their legal representative signs a written informed consent form.\n\n   Exclusion Criteria:\n   * Isolated cortical vein thrombosis or isolated cavernous sinus thrombosis;\n   * Recurrent intracranial venous sinus thrombosis;\n   * Complicated by venous cerebral infarction;\n   * Prior receipt of endovascular treatment for cerebral venous sinus\u002Finternal jugular vein, ventricular puncture drainage, or lumbar cistern drainage before enrollment;\n   * Presence of moderate to severe stenosis (≥50%) in intracranial or extracranial arteries;\n   * History of cerebral infarction, cerebral hemorrhage, or neurosurgery;\n   * Complicated by other neurological structural abnormalities such as cerebral small vessel disease, intracranial vascular malformation, dural arteriovenous fistula, intracranial infection, intracranial space-occupying lesion, severe cerebral atrophy, or hydrocephalus;\n   * Presence of other diseases affecting glymphatic function (e.g., multiple sclerosis, neuromyelitis optica spectrum disorders, systemic lupus erythematosus, obstructive sleep apnea-hypopnea syndrome, Parkinson's disease, or Alzheimer's disease);\n   * Presence of severe impaired consciousness, hearing impairment, or aphasia preventing cooperation with examinations or assessments;\n   * Contraindications to MRI (e.g., metal implants, claustrophobia, etc.) or allergy to gadolinium-based contrast agents;\n   * Other conditions deemed unsuitable for enrollment by the investigator.\n3. Healthy Control Subjects:\n\nInclusion Criteria:\n\n* Gender and age-matched;\n* No central nervous system diseases;\n* Normal scores on the HAMD-24, HAMA-14, MMSE, MoCA, and PSQI scales;\n* No cerebral venous sinus thrombosis, cerebral venous sinus stenosis, or moderate to severe intracranial\u002Fextracranial arterial stenosis;\n* No contraindications to MRI (e.g., metal implants, claustrophobia, etc.);\n* The subject or their legal representative signs a written informed consent form.",true,{"count":89,"type":19},149,"Cerebral venous disorders, including cerebral venous sinus stenosis (CVSS) and cerebral venous sinus thrombosis (CVST), can obstruct venous blood drainage, leading to intracranial hypertension. However, their effects on glymphatic function and white matter integrity in the brain remain poorly understood.\n\nTherefore, this study will enroll healthy controls, CVSS patients, and CVST patients to compare differences in glymphatic function and white matter microstructural integrity. Additionally, CVSS and CVST patients will undergo a 3-month follow-up to investigate the interrelationships and longitudinal changes among clinical parameters, glymphatic function, and white matter integrity.",[23],[93,94,95,96],"cerebral venous sinus thrombosis","cerebral venous sinus stenosis","glymphatic system","white matter integrity","2025-07-09",{"date":99,"type":39},"2025-07-18",{"date":101,"type":19},"2025-07",{"date":103,"type":19},"2026-10",{"name":105,"class":46},"Xuanwu Hospital, Beijing",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":47},"100440891","the-norwegian-cerebral-venous-thrombosis-study-100440891","NCT05021198","The Norwegian Cerebral Venous Thrombosis Study","Epidemiology, Clinical and Radiological Presentation and Long-term Prognosis of Cerebral Venous Thrombosis in a Norwegian Population (NoCVT)","NoCVT","Inclusion Criteria:\n\n* A diagnosis of CVT 2014-2023 from the 13 participating primary hospitals\n\nExclusion Criteria:\n\n* none",{"count":115,"type":19},600,"The NoCVT study will investigate CVT (2014-2023) in a large Norwegian population (\\> 3 millions) using several approaches combining existing health registries, clinical databases and new prospectively collected clinical data to explore epidemiology, risk factors, diagnostics, treatment, and the long-term prognosis of CVT.",[118,23],"Cerebral Vein Thrombosis","2025-02-03",{"date":121,"type":39},"2025-02-05",{"date":123,"type":39},"2014-01-01",{"date":125,"type":19},"2027-01",{"name":127,"class":46},"University Hospital, Akershus",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":60,"phases":139,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":47},"100560956","endovascular-treatment-or-standard-medical-care-for-cerebral-venous-sinus-thrombosisescort-100560956","NCT06583889","Endovascular Treatment or Standard Medical Care for Cerebral Venous Sinus Thrombosis(ESCORT)","Efficacy and Safety of endovasCular Treatment vs Standard Medical Care for Cerebral venOus Sinus thRombosis With mulTimodal Imaging Selection(ESCORT)","ESCORT","Inclusion Criteria:\n\nGeneral inclusion criteria\n\n1. age between 18 years and 60 years\n2. Cerebral venous sinus thrombosis (CVST), confirmed by computed tomographic and magnetic resonance imaging (T1, T2, SWI, DWI, FLAIR), magnetic resonance venography, computed tomographic venography or digital subtraction angiography.\n3. Patients with CVST who meet the following conditions (1) Within 3 weeks of acute onset (2) There are one of the obvious clinical symptoms: A. symptoms of intracranial hypertension: headache, papilledema, visual acuity and visual field damage; B. Neurological impairment symptoms; C. Seizure; D. Disturbance of consciousness (GCS score≥9)\n4. Lumbar puncture pressure≥250mmH2O\n5. Patients or their relatives can sign written informed consent\n\nImage inclusion criteria\n\n1.CT and MRI (T1, T2, MRV, SWI, DWI) are used to screen CVST as acute phase (T1 low signal, T2 equal signal or slightly high signal; CT showed that the corresponding area is high signal) or subacute phase (T1 and T2 high signal) 2.3D-TOF or CE-MRA or CTV are used to screen the types of venous sinus thrombosis occlusion of main drainage which is prone to intracranial hypertension due to venous sinus thrombosis as follows: A.Superior sagittal sinus occlusion: thrombus obliterates the posterior 1\u002F2 segment of superior sagittal sinus\n\nB.Transverse sinus occlusive type:\n\n1. complete thrombosis of the bilateral transverse sinus with or without the corresponding sigmoid sinus involvement\n2. complete thrombosis of the superior transverse sinus with or without the corresponding sigmoid sinus involvement C.complete thrombosis of the superior sagittal sinus and unilateral transverse sinus with or without the corresponding sigmoid sinus involvement D.complete thrombosis of the superior sagittal sinus and bilateral transverse sinus with the corresponding sigmoid sinus is occluded\n\nExclusion Criteria:\n\n1. Received any thrombolytic therapy within 7 days\n2. Patients who cannot cooperate or accept MRI examination\n3. Patients with dementia or mental illness are known to be unable to complete neurological function assessment and follow-up\n4. Patients with high myopia and eye diseases affecting fundus examination and visual field examination\n5. The patient has a clear history of primary headache such as migraine, tension headache and cluster headache, and a clear history of secondary headache\n6. Patients who receive major surgery (excluding lumbar puncture) or a history of severe brain injury within 2 weeks\n7. Known history of severe allergy to contrast media (excluding rash)\n8. Gastrointestinal bleeding occurred within 3 months (excluding bleeding from recto anal hemorrhoids)\n9. Serious liver function or renal dysfunction with written records and affecting normal coagulation function\n10. Hemorrhagic disease (hemorrhagic disease history) with written records\n11. Excepting for CVST, patients with any life expectancy less than 1 year (such as advanced cancer)\n12. Pregnant women (puerperal women can be enrolled)\n13. Patients with contraindications to anticoagulation or thrombolysis\n14. Intracranial infectious or malignant tumor secondary to cerebrospinal fluid\n15. CVST secondary to autoimmune diseases and hematological diseases (such as primary thrombocytosis, myelodysplastic syndrome, leukemia, etc.) and genetic factors\n16. Concurrent thrombocytopenia (\\\u003C100×109\u002FL)\n17. MRI features showed that the occluded vessels of venous sinus were in chronic phase (T1 and T2 images showed equal signal)\n18. Severe brain tissue injury symptoms such as obvious space occupying effect due to massive cerebral edema, cerebral infarction or cerebral hemorrhage\n19. Patients with CVST accompanied by ventricular compression and hydrocephalus requiring surgery\n20. Participating in clinical trials of any other drugs or medical devices, or may participate in clinical trials of any other drugs or medical devices within 6 months after being enrolled in this clinical trial\n21. The researchers judge that there are other situations that are not suitable for enrollment","60 Years",{"count":138,"type":19},224,[62],"Background: It has not been extensively studied in differing populations that endovascular treatment (EVT) for acute and subacute CVST with multimodal imaging selection improves the functional outcome better than standard medical care based on the guidelines. Published experience with endovascular treatment is promising. However, its efficacy has not been confirmed and early selection criteria for EVT are unknown.\n\nObjective:The main objective of the Endovascular treatment or Standard medical Care for Cerebral Venous Sinus Thrombosis (ESCORT) trial is to determine if EVT improves the functional outcome of acute and subacute CVST patients with multimodal imaging selection.\n\nStudy Design:The ESCORT trial is a multicenter, prospective, randomized, open-label, blinded endpoint trial.\n\nStudy population: Patients are eligible if they have a radiologically criteria proven acute and subacute CVST, obvious symptoms of intracranial hypertension(lumbar puncture pressure≥250mmH2O).\n\nIntervention: Patients will be randomized to receive either EVT or standard medical care (therapeutic doses of heparin). EVT consists of local application of alteplase or urokinase within the thrombosed sinuses, balloon angioplasty, and\u002For mechanical thrombectomy. Glasgow coma score, NIH stroke scale, ophthalmologic examination, Headache Impact Test-6(HIT-6), EuroQol-5 dimension-5 level(EQ-5D-5L) scale score, multimodal imaging and relevant laboratory parameters will be assessed at baseline.\n\nEndpoints: The primary endpoint is the proportion with good prognosis at 3 months (definition: a. mRS≤1; b. headache score (\\\u003C50, HIT-6); c. Frisén=0 grade for papilledema; d. defect of field vision PMD\\>-2dB). Secondary outcomes are three-months mRS, HIT-6,Frisén grade for papilledema, situation of EQ-5D-5L, mortality and recanalization rate. Major intracranial and extracranial hemorrhagic complications within one-week after the intervention are the principal safety outcomes. Results will be analyzed according to the'intention-to-treat' principle. Blinded assessors not involved in the treatment of the patient will assess endpoints with standardized questionnaires.\n\nStudy size: To detect a 20% relative increase of good prognosis (from 65 to 85%), 224 patients (112 in each treatment arm) have to be included (two-sided alpha, 80% power).\n\nNature and extent of the burden and risks associated with participation, benefit and group relatedness: Included patients may benefit directly from EVT. Complications of EVT, most notably intracranial hemorrhages, constitute the most important risk of the study.",[23],[27,143,144,145],"Heparin","Randomized controlled trial","Endovascular treatment","2024-09-02",{"date":148,"type":39},"2024-09-04",{"date":150,"type":39},"2024-08-09",{"date":152,"type":19},"2029-08",{"name":154,"class":46},"Beijing Tiantan Hospital",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":60,"phases":165,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":177,"leadSponsor":179,"locationsCount":47},"100558460","phase-3-dabigatran-versus-rivaroxaban-in-cerebral-venous-thrombosis-100558460","NCT06551402","Dabigatran Versus Rivaroxaban in Cerebral Venous Thrombosis","Dabigatran Versus Rivaroxaban in Cerebral Venous Thrombosis, a Randomized Controlled Trial","Inclusion Criteria:\n\n* 1-Patients aged 18 and above 2-New diagnosis of symptomatic cerebral venous thrombosis as confirmed on CT\u002FCT venogram or MRI\u002FMR venogram 3-Ability to randomize within 14 days of neuroimaging-confirmed diagnosis 4-The treating clinician thinks that the patient is appropriate for oral anticoagulation as per the standard of care 5-The patient or legally authorized representative can give written informed consent\n\nExclusion Criteria:\n\n1. The patient has known antiphospholipid antibody syndrome with a previous history of venous or arterial thrombosis\n2. The patient is anticipated to require invasive procedures (e.g., lumbar puncture, thrombectomy, hemicraniectomy) prior to initiation of oral anticoagulation\n3. Patient is unable to swallow due to depressed level of consciousness\n4. Impaired renal function (i.e., CrCl \\\u003C 30 mL\u002Fmin using CockroftGault equation)\n5. Pregnancy; if a woman is of childbearing potential a urine or serum beta human chorionic gonadotropin (β-hCG) test is positive\n6. Breastfeeding at the time of randomization\n7. Bleeding diathesis or other contraindication to anticoagulation\n8. Any concurrent medical condition requiring mandatory antiplatelet or anticoagulant use\n9. Concomitant use of strong CYP3A4 inducers (e.g., ongoing use of dilantin, carbamazepine, HIV protease inhibitors) or CYP3A4 inhibitors (e.g., diltiazem, ketoconazole)\n10. Patient has a severe or fatal comorbid illness that will prevent improvement","75 Years",{"count":164,"type":19},200,[166],"PHASE3","Along with the current clinical trial, the efficacy and safety of a 150 mg Bid dabigatran administered within 24 hours of randomization after having first-ever cerebral venous thrombosis compared to 20 mg rivaroxaban were assessed through rate of recurrent VTE, mRS, rate of venous recanalization, HIT score, MoCA test, and central and peripheral hemorrhagic complications",[23],[170,171,172,173],"rivaroxaban","dabigatran","Egypt","cerebral venous thrombosis",{"date":175,"type":39},"2024-08-13",{"date":150,"type":39},{"date":178,"type":19},"2026-11-01",{"name":180,"class":46},"Kafrelsheikh University",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":162,"enrollmentInfo":188,"targetDuration":4,"studyType":60,"phases":189,"briefSummary":190,"conditions":191,"keywords":192,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":195,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":47},"100558461","phase-3-dabigatran-versus-apixaban-in-cerebral-venous-thrombosis-100558461","NCT06551415","Dabigatran Versus Apixaban in Cerebral Venous Thrombosis","Dabigatran Versus Apixaban in Cerebral Venous Thrombosis, a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients aged 18 and above\n2. New diagnosis of symptomatic cerebral venous thrombosis as confirmed on CT\u002FCT venogram or MRI\u002FMR venogram\n3. Ability to randomize within 14 days of neuroimaging-confirmed diagnosis\n4. The treating clinician thinks that the patient is appropriate for oral anticoagulation as per the standard of care\n5. The patient or legally authorized representative can give written informed consent\n\nExclusion Criteria:\n\n1. The patient has known antiphospholipid antibody syndrome with a previous history of venous or arterial thrombosis\n2. The patient is anticipated to require invasive procedures (e.g., lumbar puncture, thrombectomy, hemicraniectomy) before initiation of oral anticoagulation\n3. Patient is unable to swallow due to a depressed level of consciousness\n4. Impaired renal function (i.e., CrCl \\\u003C 30 mL\u002Fmin using CockroftGault equation)\n5. Pregnancy: if a woman is of childbearing potential, a urine or serum beta-human chorionic gonadotropin (β-hCG) test is positive\n6. Breastfeeding at the time of randomization\n7. Bleeding diathesis or other contraindication to anticoagulation\n8. Any concurrent medical condition requiring mandatory antiplatelet or anticoagulant use\n9. Concomitant use of strong CYP3A4 inducers (e.g., ongoing use of Dilantin, carbamazepine, HIV protease inhibitors) or CYP3A4 inhibitors (e.g., diltiazem, ketoconazole)\n10. The patient has a severe or fatal comorbid illness that will prevent improvement",{"count":164,"type":19},[166],"Along with the current clinical trial, the efficacy and safety of a 150 mg Bid dabigatran administered within 24 hours of randomization after having first-ever cerebral venous thrombosis compared to apixaban 5mg Bid were assessed through rate of recurrent VTE, mRS, rate of venous recanalization, HIT score, MoCA test, and central and peripheral hemorrhagic complications",[23],[193,173,194,172],"apixaban,","Dabigatran",{"date":175,"type":39},{"date":197,"type":39},"2021-08-01",{"date":199,"type":19},"2024-10-01",{"name":180,"class":46}]